Your browser doesn't support javascript.
loading
Prolonged Opioid Use Associated With Reduced Survival After Lung Cancer Resection.
Chancellor, William Z; Mehaffey, J Hunter; Desai, Raj P; Beller, Jared; Balkrishnan, Rajesh; Walters, Dustin M; Martin, Linda W.
Afiliação
  • Chancellor WZ; Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Virginia.
  • Mehaffey JH; Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Virginia.
  • Desai RP; Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
  • Beller J; Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Virginia.
  • Balkrishnan R; Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
  • Walters DM; Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Virginia.
  • Martin LW; Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Virginia. Electronic address: lm6yb@virginia.edu.
Ann Thorac Surg ; 111(6): 1791-1798, 2021 06.
Article em En | MEDLINE | ID: mdl-33127403
ABSTRACT

BACKGROUND:

Lung cancer remains the leading cause of cancer death worldwide and the search for modifiable risk factors to improve survival is ongoing. There is a growing appreciation for a biological relationship between opioids and lung cancer progression. Our goal was to evaluate the association between perioperative opioid use and long-term survival after lung cancer resection.

METHODS:

A retrospective analysis of 2006 to 2012 Surveillance, Epidemiology, and End Results Medicare datasets identified all patients undergoing pulmonary resection for non-small cell lung cancer stages I to III. Patients were stratified by filling opioid prescriptions only 30 days before or after surgery (standard group), filling opioid prescriptions greater than 30 days before surgery (chronic group), or filling opioid prescriptions greater than 90 days after surgery but not before surgery (prolonged group). Kaplan-Meier survival analysis compared each group; risk-adjusted survival analysis was performed using the Cox proportional hazards model.

RESULTS:

We identified 3273 patients, including 1385 in the standard group (42.3%), 1441 in the chronic group (44.0%), and 447 in the prolonged group (13.7%). Of previously opioid-naive patients, 447 of 1832 (24.4%) became new prolonged opioid users. Kaplan-Meier survival analysis illustrated lower overall and disease-specific survival in chronic and prolonged opioid groups (both P < .01). After risk adjustment, chronic (hazard ratio = 1.27; 95% confidence interval, 1.09-1.47; P < .01) and prolonged (hazard ratio = 1.42; 95% confidence interval, 1.17-1.73; P < .01) opioid use were independently associated with reduced long-term survival.

CONCLUSIONS:

Chronic and prolonged opioid use were independently associated with reduced long-term, disease-specific survival after lung cancer resection. These findings provide epidemiologic support for a biological relationship between opioid use and lung cancer progression.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Duração da Terapia / Analgésicos Opioides / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Thorac Surg Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Duração da Terapia / Analgésicos Opioides / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Thorac Surg Ano de publicação: 2021 Tipo de documento: Article